[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLcbocfgHP5-udO842vds-trVc2K2b1RN0ckuck2SY8M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":8,"truncated":9,"activeTrials":10,"phase3Count":11,"totalEnrollment":12,"activePrograms":13,"nonDrugCount":14,"topConditions":15,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Celltrion",[4,6,7],"Celltrion Pharm, Inc.","Celltrion HealthCare France",84,false,11,33,26254,22,4,[16,19,22,24,26,28,30,32],{"name":17,"count":18},"Rheumatoid Arthritis",14,{"name":20,"count":21},"Healthy",12,{"name":23,"count":14},"Crohn's Disease",{"name":25,"count":14},"Essential Hypertension",{"name":27,"count":14},"Healthy Male Subjects",{"name":29,"count":14},"SARS-CoV-2 Infection",{"name":31,"count":14},"Ankylosing Spondylitis",{"name":33,"count":34},"Healthy Subjects",3,[36,41,46,51,56,61,66,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06630559","A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis","2026-02-18","CT-P55",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07200986","Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects","2026-03-31","Ixekizumab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07533539","Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers","2026-05-24","L03RD1",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07367958","A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects","2026-08","CT-P52",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07093476","Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","2026-12","Metformin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06939595","A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","2027-02","CT-P51",{"nctId":67,"briefTitle":68,"date":64,"intervention":69},"NCT05906992","A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","CT-P53",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05866614","A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps","2027-03","Remsima IV",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06997055","ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar","2027-09-30","Ustekinumab 45 mg",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06952478","A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","2027-11-15","CT-P44",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,149,172,207,229,251,273,291,314,332,356,374,392,427,449,467,488,508,535,558,576,598,616,634,652,702,759,806,853,900,945,997,1023,1071,1108,1130,1152,1188,1226,1248,1270,1306,1328,1367,1404,1426,1451,1478,1496,1525,1543,1561,1579,1604,1622,1640,1658,1676,1694,1712,1730,1762,1780,1798,1816,1834,1852,1870,1888,1914,1932,1950,1975,1993,2011,2037,2064,2082,2127,2159,2196,2222,2240,2258,2284,2302,2320,2346,2364,2382,2400,2418,2436,2454,2477,2495,2513,2531,2549,2573,2591,2618,2636,2654,2678,2696,2714,2739,2757,2775,2800,2818,2836,2854,2872,2890,2908,2932],{"intervention":60,"totalTrials":34,"cells":94},{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":132,"NA":147},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":131,"soonestReadout":59},[104,117],{"nctId":57,"briefTitle":58,"status":105,"phases":106,"primaryCompletion":59,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":114},"RECRUITING",[89],"2027-04","2025-07-18",171,[111,112,113],"T2DM","Diabete Type 2","DM",[60,115,116],"Alogliptin","empagliflozin",{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":127},"NCT06571591","Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin","COMPLETED",[89],"2026-04-16","2026-05-04","2024-08-27",606,[111],[128,129,130,60],"CT-L03 Group 1","CT-L03 Group 2","Empagliflozin",1,{"trials":133,"activeCount":97},[134],{"nctId":135,"briefTitle":136,"status":120,"phases":137,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":144},"NCT03499704","A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy",[90],"2024-01-02","2024-01-16","2020-02-11",133,[143],"Diabetes Mellitus, Type 2",[145,115,60,146],"Pioglitazone + Alogliptin","Dapagliflozin",{"trials":148,"activeCount":97},[],{"intervention":115,"totalTrials":150,"cells":151},2,{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":164,"NA":170},{"trials":153,"activeCount":97},[],{"trials":155,"activeCount":97},[],{"trials":157,"activeCount":97},[],{"trials":159,"activeCount":131,"soonestReadout":59},[160],{"nctId":57,"briefTitle":58,"status":105,"phases":161,"primaryCompletion":59,"completion":107,"start":108,"enrollment":109,"conditions":162,"interventions":163},[89],[111,112,113],[60,115,116],{"trials":165,"activeCount":97},[166],{"nctId":135,"briefTitle":136,"status":120,"phases":167,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":168,"interventions":169},[90],[143],[145,115,60,146],{"trials":171,"activeCount":97},[],{"intervention":40,"totalTrials":150,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":190,"PHASE3":192,"PHASE4":203,"NA":205},{"trials":175,"activeCount":97},[],{"trials":177,"activeCount":97},[178],{"nctId":179,"briefTitle":180,"status":120,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":187},"NCT07054970","To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects",[87],"2024-08-29","2024-09-06","2024-01-12",172,[27],[40,188,189],"US-licensed Cosentyx","EU-approved Cosentyx",{"trials":191,"activeCount":97},[],{"trials":193,"activeCount":131,"soonestReadout":39},[194],{"nctId":37,"briefTitle":38,"status":195,"phases":196,"primaryCompletion":39,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":202},"ACTIVE_NOT_RECRUITING",[89],"2026-10","2025-05-26",153,[201],"Plaque Psoriasis",[40,189],{"trials":204,"activeCount":97},[],{"trials":206,"activeCount":97},[],{"intervention":189,"totalTrials":150,"cells":208},{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":217,"PHASE3":219,"PHASE4":225,"NA":227},{"trials":210,"activeCount":97},[],{"trials":212,"activeCount":97},[213],{"nctId":179,"briefTitle":180,"status":120,"phases":214,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":215,"interventions":216},[87],[27],[40,188,189],{"trials":218,"activeCount":97},[],{"trials":220,"activeCount":131,"soonestReadout":39},[221],{"nctId":37,"briefTitle":38,"status":195,"phases":222,"primaryCompletion":39,"completion":197,"start":198,"enrollment":199,"conditions":223,"interventions":224},[89],[201],[40,189],{"trials":226,"activeCount":97},[],{"trials":228,"activeCount":97},[],{"intervention":116,"totalTrials":150,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":247,"NA":249},{"trials":232,"activeCount":97},[],{"trials":234,"activeCount":97},[],{"trials":236,"activeCount":97},[],{"trials":238,"activeCount":131,"soonestReadout":59},[239,243],{"nctId":57,"briefTitle":58,"status":105,"phases":240,"primaryCompletion":59,"completion":107,"start":108,"enrollment":109,"conditions":241,"interventions":242},[89],[111,112,113],[60,115,116],{"nctId":118,"briefTitle":119,"status":120,"phases":244,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":245,"interventions":246},[89],[111],[128,129,130,60],{"trials":248,"activeCount":97},[],{"trials":250,"activeCount":97},[],{"intervention":65,"totalTrials":131,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":269,"NA":271},{"trials":254,"activeCount":97},[],{"trials":256,"activeCount":97},[],{"trials":258,"activeCount":97},[],{"trials":260,"activeCount":131,"soonestReadout":64},[261],{"nctId":62,"briefTitle":63,"status":105,"phases":262,"primaryCompletion":64,"completion":263,"start":264,"enrollment":125,"conditions":265,"interventions":267},[89],"2028-07","2025-01-30",[266],"Non Squamous Non Small Cell Lung Cancer",[65,268],"EU-approved Keytruda",{"trials":270,"activeCount":97},[],{"trials":272,"activeCount":97},[],{"intervention":268,"totalTrials":131,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":287,"NA":289},{"trials":276,"activeCount":97},[],{"trials":278,"activeCount":97},[],{"trials":280,"activeCount":97},[],{"trials":282,"activeCount":131,"soonestReadout":64},[283],{"nctId":62,"briefTitle":63,"status":105,"phases":284,"primaryCompletion":64,"completion":263,"start":264,"enrollment":125,"conditions":285,"interventions":286},[89],[266],[65,268],{"trials":288,"activeCount":97},[],{"trials":290,"activeCount":97},[],{"intervention":84,"totalTrials":131,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":310,"NA":312},{"trials":294,"activeCount":97},[],{"trials":296,"activeCount":97},[],{"trials":298,"activeCount":97},[],{"trials":300,"activeCount":131,"soonestReadout":83},[301],{"nctId":81,"briefTitle":82,"status":105,"phases":302,"primaryCompletion":83,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},[89],"2029-06-25","2025-08-12",486,[307],"Refractory or Relapsed Multiple Myeloma",[84,309],"Darzalex Faspro",{"trials":311,"activeCount":97},[],{"trials":313,"activeCount":97},[],{"intervention":309,"totalTrials":131,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":328,"NA":330},{"trials":317,"activeCount":97},[],{"trials":319,"activeCount":97},[],{"trials":321,"activeCount":97},[],{"trials":323,"activeCount":131,"soonestReadout":83},[324],{"nctId":81,"briefTitle":82,"status":105,"phases":325,"primaryCompletion":83,"completion":303,"start":304,"enrollment":305,"conditions":326,"interventions":327},[89],[307],[84,309],{"trials":329,"activeCount":97},[],{"trials":331,"activeCount":97},[],{"intervention":69,"totalTrials":131,"cells":333},{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":340,"PHASE4":352,"NA":354},{"trials":335,"activeCount":97},[],{"trials":337,"activeCount":97},[],{"trials":339,"activeCount":97},[],{"trials":341,"activeCount":131,"soonestReadout":64},[342],{"nctId":67,"briefTitle":68,"status":105,"phases":343,"primaryCompletion":64,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},[89],"2029-01","2024-01-11",512,[348],"Relapsing-remitting Multiple Sclerosis",[69,350,351],"US-Ocrevus","EU-Ocrevus",{"trials":353,"activeCount":97},[],{"trials":355,"activeCount":97},[],{"intervention":350,"totalTrials":131,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":370,"NA":372},{"trials":359,"activeCount":97},[],{"trials":361,"activeCount":97},[],{"trials":363,"activeCount":97},[],{"trials":365,"activeCount":131,"soonestReadout":64},[366],{"nctId":67,"briefTitle":68,"status":105,"phases":367,"primaryCompletion":64,"completion":344,"start":345,"enrollment":346,"conditions":368,"interventions":369},[89],[348],[69,350,351],{"trials":371,"activeCount":97},[],{"trials":373,"activeCount":97},[],{"intervention":351,"totalTrials":131,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":388,"NA":390},{"trials":377,"activeCount":97},[],{"trials":379,"activeCount":97},[],{"trials":381,"activeCount":97},[],{"trials":383,"activeCount":131,"soonestReadout":64},[384],{"nctId":67,"briefTitle":68,"status":105,"phases":385,"primaryCompletion":64,"completion":344,"start":345,"enrollment":346,"conditions":386,"interventions":387},[89],[348],[69,350,351],{"trials":389,"activeCount":97},[],{"trials":391,"activeCount":97},[],{"intervention":50,"totalTrials":150,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":395,"activeCount":97},[],{"trials":397,"activeCount":131,"soonestReadout":49},[398,408],{"nctId":47,"briefTitle":48,"status":195,"phases":399,"primaryCompletion":49,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":405},[87],"2026-06-07","2026-05-09",48,[404],"Type 2 Diabetes Mellitus (T2DM)",[50,406,407],"L03RD2","L03TD1",{"nctId":409,"briefTitle":410,"status":120,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":417},"NCT07158346","Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers",[87],"2025-10-03","2025-10-23","2025-08-18",49,[404],[50,406,418],"CT-L03",{"trials":420,"activeCount":97},[],{"trials":422,"activeCount":97},[],{"trials":424,"activeCount":97},[],{"trials":426,"activeCount":97},[],{"intervention":406,"totalTrials":150,"cells":428},{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":447},{"trials":430,"activeCount":97},[],{"trials":432,"activeCount":131,"soonestReadout":49},[433,437],{"nctId":47,"briefTitle":48,"status":195,"phases":434,"primaryCompletion":49,"completion":400,"start":401,"enrollment":402,"conditions":435,"interventions":436},[87],[404],[50,406,407],{"nctId":409,"briefTitle":410,"status":120,"phases":438,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":439,"interventions":440},[87],[404],[50,406,418],{"trials":442,"activeCount":97},[],{"trials":444,"activeCount":97},[],{"trials":446,"activeCount":97},[],{"trials":448,"activeCount":97},[],{"intervention":407,"totalTrials":131,"cells":450},{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":452,"activeCount":97},[],{"trials":454,"activeCount":131,"soonestReadout":49},[455],{"nctId":47,"briefTitle":48,"status":195,"phases":456,"primaryCompletion":49,"completion":400,"start":401,"enrollment":402,"conditions":457,"interventions":458},[87],[404],[50,406,407],{"trials":460,"activeCount":97},[],{"trials":462,"activeCount":97},[],{"trials":464,"activeCount":97},[],{"trials":466,"activeCount":97},[],{"intervention":55,"totalTrials":131,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":470,"activeCount":97},[],{"trials":472,"activeCount":131,"soonestReadout":54},[473],{"nctId":52,"briefTitle":53,"status":195,"phases":474,"primaryCompletion":54,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":479},[87],"2027-01","2026-01-26",218,[27],[55],{"trials":481,"activeCount":97},[],{"trials":483,"activeCount":97},[],{"trials":485,"activeCount":97},[],{"trials":487,"activeCount":97},[],{"intervention":45,"totalTrials":131,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":491,"activeCount":97},[],{"trials":493,"activeCount":131,"soonestReadout":44},[494],{"nctId":42,"briefTitle":43,"status":195,"phases":495,"primaryCompletion":44,"completion":44,"start":496,"enrollment":477,"conditions":497,"interventions":499},[87],"2025-09-17",[498],"Healthy Participants",[45],{"trials":501,"activeCount":97},[],{"trials":503,"activeCount":97},[],{"trials":505,"activeCount":97},[],{"trials":507,"activeCount":97},[],{"intervention":509,"totalTrials":131,"cells":510},"Omalizumab",{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":512,"activeCount":97},[],{"trials":514,"activeCount":97},[],{"trials":516,"activeCount":97},[],{"trials":518,"activeCount":97},[],{"trials":520,"activeCount":97},[],{"trials":522,"activeCount":131,"soonestReadout":527},[523],{"nctId":524,"briefTitle":525,"status":105,"phases":526,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":534},"NCT07425639","ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar",[],"2028-03","2028-09","2025-10-02",225,[532,533],"Chronic Spontaneous Urticaria (CSU)","Allergic Asthma",[509],{"intervention":74,"totalTrials":131,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":538,"activeCount":97},[],{"trials":540,"activeCount":97},[],{"trials":542,"activeCount":97},[],{"trials":544,"activeCount":97},[],{"trials":546,"activeCount":97},[],{"trials":548,"activeCount":131,"soonestReadout":73},[549],{"nctId":71,"briefTitle":72,"status":195,"phases":550,"primaryCompletion":73,"completion":73,"start":551,"enrollment":552,"conditions":553,"interventions":556},[],"2023-01-13",881,[17,31,554,555],"Psoriatic Arthritis","Psoriasis",[74,557],"Remsima SC",{"intervention":557,"totalTrials":131,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":561,"activeCount":97},[],{"trials":563,"activeCount":97},[],{"trials":565,"activeCount":97},[],{"trials":567,"activeCount":97},[],{"trials":569,"activeCount":97},[],{"trials":571,"activeCount":131,"soonestReadout":73},[572],{"nctId":71,"briefTitle":72,"status":195,"phases":573,"primaryCompletion":73,"completion":73,"start":551,"enrollment":552,"conditions":574,"interventions":575},[],[17,31,554,555],[74,557],{"intervention":79,"totalTrials":131,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":586,"NA":588},{"trials":579,"activeCount":97},[],{"trials":581,"activeCount":97},[],{"trials":583,"activeCount":97},[],{"trials":585,"activeCount":97},[],{"trials":587,"activeCount":97},[],{"trials":589,"activeCount":131,"soonestReadout":78},[590],{"nctId":76,"briefTitle":77,"status":105,"phases":591,"primaryCompletion":78,"completion":592,"start":593,"enrollment":530,"conditions":594,"interventions":596},[],"2027-12-31","2025-03-17",[595,201],"Crohn Disease",[79,597],"Ustekinumab 90 mg",{"intervention":597,"totalTrials":131,"cells":599},{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":601,"activeCount":97},[],{"trials":603,"activeCount":97},[],{"trials":605,"activeCount":97},[],{"trials":607,"activeCount":97},[],{"trials":609,"activeCount":97},[],{"trials":611,"activeCount":131,"soonestReadout":78},[612],{"nctId":76,"briefTitle":77,"status":105,"phases":613,"primaryCompletion":78,"completion":592,"start":593,"enrollment":530,"conditions":614,"interventions":615},[],[595,201],[79,597],{"intervention":145,"totalTrials":131,"cells":617},{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":632},{"trials":619,"activeCount":97},[],{"trials":621,"activeCount":97},[],{"trials":623,"activeCount":97},[],{"trials":625,"activeCount":97},[],{"trials":627,"activeCount":97},[628],{"nctId":135,"briefTitle":136,"status":120,"phases":629,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":630,"interventions":631},[90],[143],[145,115,60,146],{"trials":633,"activeCount":97},[],{"intervention":146,"totalTrials":131,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":644,"NA":650},{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":97},[],{"trials":641,"activeCount":97},[],{"trials":643,"activeCount":97},[],{"trials":645,"activeCount":97},[646],{"nctId":135,"briefTitle":136,"status":120,"phases":647,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":648,"interventions":649},[90],[143],[145,115,60,146],{"trials":651,"activeCount":97},[],{"intervention":653,"totalTrials":14,"cells":654},"Infliximab",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":678,"PHASE3":680,"PHASE4":698,"NA":700},{"trials":656,"activeCount":97},[],{"trials":658,"activeCount":97},[659,669],{"nctId":660,"briefTitle":661,"status":120,"phases":662,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT01220518","Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)",[87],"2011-11","2012-06","2010-10",257,[31],[653],{"nctId":670,"briefTitle":671,"status":120,"phases":672,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":677},"NCT01571206","An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1",[87],"2013-05","2012-03",174,[31],[653],{"trials":679,"activeCount":97},[],{"trials":681,"activeCount":97},[682,690],{"nctId":683,"briefTitle":684,"status":120,"phases":685,"primaryCompletion":686,"completion":686,"start":674,"enrollment":687,"conditions":688,"interventions":689},"NCT01571219","An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1",[89],"2013-07",302,[17],[653],{"nctId":691,"briefTitle":692,"status":120,"phases":693,"primaryCompletion":663,"completion":694,"start":665,"enrollment":695,"conditions":696,"interventions":697},"NCT01217086","Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)",[89],"2012-07",617,[17],[653],{"trials":699,"activeCount":97},[],{"trials":701,"activeCount":97},[],{"intervention":703,"totalTrials":14,"cells":704},"CT-P13",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":720,"PHASE3":722,"PHASE4":755,"NA":757},{"trials":706,"activeCount":97},[],{"trials":708,"activeCount":97},[709],{"nctId":710,"briefTitle":711,"status":120,"phases":712,"primaryCompletion":713,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":719},"NCT02883452","A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis",[87],"2019-02-04","2019-10-02","2016-09-29",181,[23,718],"Ulcerative Colitis (Part 2 Only)",[703,703,703,703,703,703],{"trials":721,"activeCount":97},[],{"trials":723,"activeCount":97},[724,734,745],{"nctId":725,"briefTitle":726,"status":120,"phases":727,"primaryCompletion":728,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":733},"NCT03147248","A Phase I\u002FIII Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA",[89],"2018-05-21","2019-04-15","2016-09-12",407,[17],[703,703,703,703,703,703],{"nctId":735,"briefTitle":736,"status":120,"phases":737,"primaryCompletion":738,"completion":739,"start":740,"enrollment":741,"conditions":742,"interventions":743},"NCT02096861","Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease",[89],"2016-01-11","2017-02-15","2014-09-19",220,[23],[703,744],"Remicade",{"nctId":746,"briefTitle":747,"status":120,"phases":748,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":754},"NCT03707535","To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis",[89],"2020-03-16","2021-03-05","2018-11-12",270,[17],[703,744],{"trials":756,"activeCount":97},[],{"trials":758,"activeCount":97},[],{"intervention":760,"totalTrials":34,"cells":761},"CT-P41",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":787,"PHASE3":789,"PHASE4":802,"NA":804},{"trials":763,"activeCount":97},[],{"trials":765,"activeCount":97},[766,776],{"nctId":767,"briefTitle":768,"status":120,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":774},"NCT04512872","A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects",[87],"2021-05-04","2020-10-20",30,[27],[760,775],"EU-approved Prolia",{"nctId":777,"briefTitle":778,"status":120,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":785},"NCT06037395","Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects",[87],"2022-10-20","2021-10-06",154,[784],"Healthy Subject",[760,786],"US-licensed Prolia",{"trials":788,"activeCount":97},[],{"trials":790,"activeCount":97},[791],{"nctId":792,"briefTitle":793,"status":120,"phases":794,"primaryCompletion":795,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":801},"NCT04757376","A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis",[89],"2023-05-18","2023-11-16","2021-06-17",479,[800],"Postmenopausal Women With Osteoporosis",[760,786],{"trials":803,"activeCount":97},[],{"trials":805,"activeCount":97},[],{"intervention":807,"totalTrials":34,"cells":808},"CT-P17",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":834,"PHASE3":836,"PHASE4":849,"NA":851},{"trials":810,"activeCount":97},[],{"trials":812,"activeCount":97},[813,822],{"nctId":814,"briefTitle":815,"status":120,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":821},"NCT04295356","To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17",[87],"2019-11-15","2019-06-21",180,[20],[807,807],{"nctId":823,"briefTitle":824,"status":120,"phases":825,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":831},"NCT03970824","To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects",[87],"2019-11-13","2020-01-15","2019-05-31",312,[20],[807,832,833],"US-licensed Humira","EU-approved Humira",{"trials":835,"activeCount":97},[],{"trials":837,"activeCount":97},[838],{"nctId":839,"briefTitle":840,"status":120,"phases":841,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":848},"NCT05495568","To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis",[89],"2023-08-14","2024-02-05","2022-11-07",367,[847],"Moderate to Severe Chronic Plaque Psoriasis",[807,833],{"trials":850,"activeCount":97},[],{"trials":852,"activeCount":97},[],{"intervention":854,"totalTrials":34,"cells":855},"CT-P43",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":881,"PHASE3":883,"PHASE4":896,"NA":898},{"trials":857,"activeCount":97},[],{"trials":859,"activeCount":97},[860,871],{"nctId":861,"briefTitle":862,"status":120,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":868},"NCT04428814","Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects",[87],"2021-02-24","2020-08-03",271,[33],[854,869,870],"EU-approved Stelara","US-licensed Stelara",{"nctId":872,"briefTitle":873,"status":120,"phases":874,"primaryCompletion":875,"completion":876,"start":877,"enrollment":878,"conditions":879,"interventions":880},"NCT06951828","A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects",[87],"2025-11-26","2025-12-24","2025-05-30",162,[27],[854,854],{"trials":882,"activeCount":97},[],{"trials":884,"activeCount":97},[885],{"nctId":886,"briefTitle":887,"status":120,"phases":888,"primaryCompletion":889,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":894},"NCT04673786","A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis",[89],"2021-08-04","2022-05-12","2021-01-11",509,[555],[854,895],"Stelara",{"trials":897,"activeCount":97},[],{"trials":899,"activeCount":97},[],{"intervention":901,"totalTrials":34,"cells":902},"CT-P59",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":927,"PHASE3":929,"PHASE4":941,"NA":943},{"trials":904,"activeCount":97},[],{"trials":906,"activeCount":97},[907,917],{"nctId":908,"briefTitle":909,"status":120,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":915,"interventions":916},"NCT04593641","This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)",[87],"2020-10-26","2021-04-05","2020-09-04",18,[29],[901],{"nctId":918,"briefTitle":919,"status":120,"phases":920,"primaryCompletion":921,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT04525079","To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects",[87],"2020-08-07","2020-11-05","2020-07-18",32,[29],[901],{"trials":928,"activeCount":97},[],{"trials":930,"activeCount":97},[931],{"nctId":932,"briefTitle":933,"status":120,"phases":934,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":939,"interventions":940},"NCT04602000","A Phase 2\u002F3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection",[88,89],"2021-05-21","2021-10-20","2020-10-05",1642,[29],[901,901,901],{"trials":942,"activeCount":97},[],{"trials":944,"activeCount":97},[],{"intervention":946,"totalTrials":34,"cells":947},"Rituxan",{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":993,"NA":995},{"trials":949,"activeCount":97},[],{"trials":951,"activeCount":97},[],{"trials":953,"activeCount":97},[],{"trials":955,"activeCount":97},[956,971,982],{"nctId":957,"briefTitle":958,"status":120,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":966},"NCT02162771","To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan",[89],"2016-01-12","2018-12-29","2014-07-14",140,[965],"Lymphoma, Follicular",[946,967,968,969,970],"CT-P10","Cyclophosphamide","Vincristine","Prednisone",{"nctId":972,"briefTitle":973,"status":120,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":980},"NCT02149121","PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis",[89],"2016-01","2017-01","2014-08",384,[17],[967,946,981],"MabThera",{"nctId":983,"briefTitle":984,"status":120,"phases":985,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":992},"NCT02260804","To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma",[89],"2018-01-04","2019-09-04","2015-11-09",258,[991],"Follicular Lymphoma",[967,946],{"trials":994,"activeCount":97},[],{"trials":996,"activeCount":97},[],{"intervention":967,"totalTrials":34,"cells":998},{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1005,"PHASE4":1019,"NA":1021},{"trials":1000,"activeCount":97},[],{"trials":1002,"activeCount":97},[],{"trials":1004,"activeCount":97},[],{"trials":1006,"activeCount":97},[1007,1011,1015],{"nctId":957,"briefTitle":958,"status":120,"phases":1008,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":1009,"interventions":1010},[89],[965],[946,967,968,969,970],{"nctId":972,"briefTitle":973,"status":120,"phases":1012,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":1013,"interventions":1014},[89],[17],[967,946,981],{"nctId":983,"briefTitle":984,"status":120,"phases":1016,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":1017,"interventions":1018},[89],[991],[967,946],{"trials":1020,"activeCount":97},[],{"trials":1022,"activeCount":97},[],{"intervention":1024,"totalTrials":34,"cells":1025},"CT-P47",{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1052,"PHASE3":1054,"PHASE4":1067,"NA":1069},{"trials":1027,"activeCount":97},[],{"trials":1029,"activeCount":97},[1030,1042],{"nctId":1031,"briefTitle":1032,"status":1033,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1040},"NCT05188378","A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects","UNKNOWN",[87],"2022-10-01","2023-01-31","2021-12-22",300,[33],[1024,1041],"EU-approved RoActemra,",{"nctId":1043,"briefTitle":1044,"status":1033,"phases":1045,"primaryCompletion":1046,"completion":1047,"start":1048,"enrollment":1049,"conditions":1050,"interventions":1051},"NCT05617183","Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects",[87],"2023-04","2023-09","2022-11-15",268,[33],[1024,1024],{"trials":1053,"activeCount":97},[],{"trials":1055,"activeCount":97},[1056],{"nctId":1057,"briefTitle":1058,"status":120,"phases":1059,"primaryCompletion":1060,"completion":1061,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1065},"NCT05489224","A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis",[89],"2023-06-29","2023-11-23","2022-09-14",471,[17],[1024,1066],"EU-approved RoActemra",{"trials":1068,"activeCount":97},[],{"trials":1070,"activeCount":97},[],{"intervention":1072,"totalTrials":150,"cells":1073},"CT-P6",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1093,"PHASE4":1104,"NA":1106},{"trials":1075,"activeCount":97},[],{"trials":1077,"activeCount":97},[],{"trials":1079,"activeCount":97},[1080],{"nctId":1081,"briefTitle":1082,"status":120,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1090},"NCT01084863","Evaluate Safety, Efficacy and Pharmacokinetics",[87,88],"2011-12","2023-12","2010-02",143,[1089],"Metastatic Breast Cancer",[1072,1091,1092],"Herceptin","Paclitaxel",{"trials":1094,"activeCount":97},[1095],{"nctId":1096,"briefTitle":1097,"status":120,"phases":1098,"primaryCompletion":694,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT01084876","Demonstrate Efficacy and Safety of Metastatic Breast Cancer",[89],"2015-03","2010-06",475,[1089],[1072,1091,1092],{"trials":1105,"activeCount":97},[],{"trials":1107,"activeCount":97},[],{"intervention":1091,"totalTrials":150,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1120,"PHASE4":1126,"NA":1128},{"trials":1111,"activeCount":97},[],{"trials":1113,"activeCount":97},[],{"trials":1115,"activeCount":97},[1116],{"nctId":1081,"briefTitle":1082,"status":120,"phases":1117,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1118,"interventions":1119},[87,88],[1089],[1072,1091,1092],{"trials":1121,"activeCount":97},[1122],{"nctId":1096,"briefTitle":1097,"status":120,"phases":1123,"primaryCompletion":694,"completion":1099,"start":1100,"enrollment":1101,"conditions":1124,"interventions":1125},[89],[1089],[1072,1091,1092],{"trials":1127,"activeCount":97},[],{"trials":1129,"activeCount":97},[],{"intervention":1092,"totalTrials":150,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1142,"PHASE4":1148,"NA":1150},{"trials":1133,"activeCount":97},[],{"trials":1135,"activeCount":97},[],{"trials":1137,"activeCount":97},[1138],{"nctId":1081,"briefTitle":1082,"status":120,"phases":1139,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1140,"interventions":1141},[87,88],[1089],[1072,1091,1092],{"trials":1143,"activeCount":97},[1144],{"nctId":1096,"briefTitle":1097,"status":120,"phases":1145,"primaryCompletion":694,"completion":1099,"start":1100,"enrollment":1101,"conditions":1146,"interventions":1147},[89],[1089],[1072,1091,1092],{"trials":1149,"activeCount":97},[],{"trials":1151,"activeCount":97},[],{"intervention":1153,"totalTrials":150,"cells":1154},"CT-P13 SC",{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1161,"PHASE4":1184,"NA":1186},{"trials":1156,"activeCount":97},[],{"trials":1158,"activeCount":97},[],{"trials":1160,"activeCount":97},[],{"trials":1162,"activeCount":97},[1163,1173],{"nctId":1164,"briefTitle":1165,"status":120,"phases":1166,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1172},"NCT03945019","CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)",[89],"2022-08-23","2023-08-22","2019-10-28",396,[23],[1153],{"nctId":1174,"briefTitle":1175,"status":120,"phases":1176,"primaryCompletion":1177,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1183},"NCT04205643","CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)",[89],"2022-07-07","2023-07-11","2020-09-01",548,[1182],"Ulcerative Colitis",[1153],{"trials":1185,"activeCount":97},[],{"trials":1187,"activeCount":97},[],{"intervention":1189,"totalTrials":150,"cells":1190},"CT-P39",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1207,"PHASE3":1209,"PHASE4":1222,"NA":1224},{"trials":1192,"activeCount":97},[],{"trials":1194,"activeCount":97},[1195],{"nctId":1196,"briefTitle":1197,"status":120,"phases":1198,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1204},"NCT04018313","To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects",[87],"2021-03-27","2021-04-30","2020-05-28",176,[20],[1189,1205,1189,1205,1206],"EU-approved Xolair","US-licensed Xolair",{"trials":1208,"activeCount":97},[],{"trials":1210,"activeCount":97},[1211],{"nctId":1212,"briefTitle":1213,"status":120,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1221},"NCT04426890","To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria",[89],"2022-10-21","2023-04-27","2020-12-09",634,[1220],"Chronic Spontaneous Urticaria",[1189,1205],{"trials":1223,"activeCount":97},[],{"trials":1225,"activeCount":97},[],{"intervention":1205,"totalTrials":150,"cells":1227},{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1236,"PHASE3":1238,"PHASE4":1244,"NA":1246},{"trials":1229,"activeCount":97},[],{"trials":1231,"activeCount":97},[1232],{"nctId":1196,"briefTitle":1197,"status":120,"phases":1233,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":1234,"interventions":1235},[87],[20],[1189,1205,1189,1205,1206],{"trials":1237,"activeCount":97},[],{"trials":1239,"activeCount":97},[1240],{"nctId":1212,"briefTitle":1213,"status":120,"phases":1241,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1242,"interventions":1243},[89],[1220],[1189,1205],{"trials":1245,"activeCount":97},[],{"trials":1247,"activeCount":97},[],{"intervention":786,"totalTrials":150,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1258,"PHASE3":1260,"PHASE4":1266,"NA":1268},{"trials":1251,"activeCount":97},[],{"trials":1253,"activeCount":97},[1254],{"nctId":777,"briefTitle":778,"status":120,"phases":1255,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":1256,"interventions":1257},[87],[784],[760,786],{"trials":1259,"activeCount":97},[],{"trials":1261,"activeCount":97},[1262],{"nctId":792,"briefTitle":793,"status":120,"phases":1263,"primaryCompletion":795,"completion":796,"start":797,"enrollment":798,"conditions":1264,"interventions":1265},[89],[800],[760,786],{"trials":1267,"activeCount":97},[],{"trials":1269,"activeCount":97},[],{"intervention":1271,"totalTrials":150,"cells":1272},"Trastuzumab",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1287,"PHASE3":1289,"PHASE4":1302,"NA":1304},{"trials":1274,"activeCount":97},[],{"trials":1276,"activeCount":97},[1277],{"nctId":1278,"briefTitle":1279,"status":120,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1286},"NCT02665637","Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin",[87],"2016-04","2015-12",70,[1285],"Healthy Volunteers",[1271],{"trials":1288,"activeCount":97},[],{"trials":1290,"activeCount":97},[1291],{"nctId":1292,"briefTitle":1293,"status":120,"phases":1294,"primaryCompletion":1295,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT02162667","Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer",[89],"2016-05-26","2018-10","2014-06",562,[1300],"HER2-positive Carcinoma of Breast",[1271],{"trials":1303,"activeCount":97},[],{"trials":1305,"activeCount":97},[],{"intervention":833,"totalTrials":150,"cells":1307},{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1316,"PHASE3":1318,"PHASE4":1324,"NA":1326},{"trials":1309,"activeCount":97},[],{"trials":1311,"activeCount":97},[1312],{"nctId":823,"briefTitle":824,"status":120,"phases":1313,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":1314,"interventions":1315},[87],[20],[807,832,833],{"trials":1317,"activeCount":97},[],{"trials":1319,"activeCount":97},[1320],{"nctId":839,"briefTitle":840,"status":120,"phases":1321,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":1322,"interventions":1323},[89],[847],[807,833],{"trials":1325,"activeCount":97},[],{"trials":1327,"activeCount":97},[],{"intervention":1329,"totalTrials":150,"cells":1330},"CT-P16",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1347,"PHASE3":1349,"PHASE4":1363,"NA":1365},{"trials":1332,"activeCount":97},[],{"trials":1334,"activeCount":97},[1335],{"nctId":1336,"briefTitle":1337,"status":120,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1343,"interventions":1344},"NCT03247673","To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin",[87],"2017-12-22","2018-01-17","2017-08-07",141,[20],[1329,1345,1346],"EU-approved Avastin","US-licensed Avastin",{"trials":1348,"activeCount":97},[],{"trials":1350,"activeCount":97},[1351],{"nctId":1352,"briefTitle":1353,"status":120,"phases":1354,"primaryCompletion":1355,"completion":1356,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT03676192","To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer",[89],"2021-04-22","2023-09-19","2019-02-01",689,[1360],"Adenocarcinoma of Lung",[1329,1362],"Avastin",{"trials":1364,"activeCount":97},[],{"trials":1366,"activeCount":97},[],{"intervention":1368,"totalTrials":150,"cells":1369},"CT-P13 SC Auto-Injector",{"EARLY_PHASE1":1370,"PHASE1":1372,"PHASE2":1385,"PHASE3":1387,"PHASE4":1400,"NA":1402},{"trials":1371,"activeCount":97},[],{"trials":1373,"activeCount":97},[1374],{"nctId":1375,"briefTitle":1376,"status":120,"phases":1377,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":477,"conditions":1380,"interventions":1382},"NCT03446976","CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects",[87],"2018-07-26","2018-02-21",[1381],"Health, Subjective",[1383,1384],"CT-P13 SC Auto-injector","CT-P13 SC Pre-filled Syringe",{"trials":1386,"activeCount":97},[],{"trials":1388,"activeCount":97},[1389],{"nctId":1390,"briefTitle":1391,"status":120,"phases":1392,"primaryCompletion":1393,"completion":1394,"start":1395,"enrollment":1396,"conditions":1397,"interventions":1399},"NCT06738719","A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis",[89],"2025-06-25","2026-04-13","2025-01-03",192,[1398],"Moderately to Severely Active Rheumatoid Arthritis",[1368],{"trials":1401,"activeCount":97},[],{"trials":1403,"activeCount":97},[],{"intervention":744,"totalTrials":150,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1422,"NA":1424},{"trials":1407,"activeCount":97},[],{"trials":1409,"activeCount":97},[],{"trials":1411,"activeCount":97},[],{"trials":1413,"activeCount":97},[1414,1418],{"nctId":735,"briefTitle":736,"status":120,"phases":1415,"primaryCompletion":738,"completion":739,"start":740,"enrollment":741,"conditions":1416,"interventions":1417},[89],[23],[703,744],{"nctId":746,"briefTitle":747,"status":120,"phases":1419,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":1420,"interventions":1421},[89],[17],[703,744],{"trials":1423,"activeCount":97},[],{"trials":1425,"activeCount":97},[],{"intervention":1427,"totalTrials":131,"cells":1428},"CT-P17 SC AI",{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1447,"NA":1449},{"trials":1430,"activeCount":97},[],{"trials":1432,"activeCount":97},[],{"trials":1434,"activeCount":97},[],{"trials":1436,"activeCount":97},[1437],{"nctId":1438,"briefTitle":1439,"status":120,"phases":1440,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1446},"NCT04171414","A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis",[89],"2019-11-04","2020-04-24","2019-09-09",62,[17],[1427],{"trials":1448,"activeCount":97},[],{"trials":1450,"activeCount":97},[],{"intervention":1452,"totalTrials":131,"cells":1453},"CT-P42",{"EARLY_PHASE1":1454,"PHASE1":1456,"PHASE2":1458,"PHASE3":1460,"PHASE4":1474,"NA":1476},{"trials":1455,"activeCount":97},[],{"trials":1457,"activeCount":97},[],{"trials":1459,"activeCount":97},[],{"trials":1461,"activeCount":97},[1462],{"nctId":1463,"briefTitle":1464,"status":120,"phases":1465,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1472},"NCT04739306","Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema",[89],"2022-10-14","2023-04-24","2021-07-22",348,[1471],"Diabetic Macular Edema (DME)",[1452,1473],"Eylea",{"trials":1475,"activeCount":97},[],{"trials":1477,"activeCount":97},[],{"intervention":1473,"totalTrials":131,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":97},[],{"trials":1483,"activeCount":97},[],{"trials":1485,"activeCount":97},[],{"trials":1487,"activeCount":97},[1488],{"nctId":1463,"briefTitle":1464,"status":120,"phases":1489,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1469,"conditions":1490,"interventions":1491},[89],[1471],[1452,1473],{"trials":1493,"activeCount":97},[],{"trials":1495,"activeCount":97},[],{"intervention":1497,"totalTrials":131,"cells":1498},"Amlodipine",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1503,"PHASE3":1505,"PHASE4":1521,"NA":1523},{"trials":1500,"activeCount":97},[],{"trials":1502,"activeCount":97},[],{"trials":1504,"activeCount":97},[],{"trials":1506,"activeCount":97},[1507],{"nctId":1508,"briefTitle":1509,"status":120,"phases":1510,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1517},"NCT07564726","Efficacy and Safety of Ezetimibe\u002FRosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol",[89],"2024-02-13","2022-08-05",163,[1515,1516],"Hypertension","Hypercholesterolemia",[1497,1518,1519,1520],"Ezetimibe\u002FRosuvastatin","Ezetimibe\u002FRosuvastatin Placebo","Amlodipine Placebo",{"trials":1522,"activeCount":97},[],{"trials":1524,"activeCount":97},[],{"intervention":1518,"totalTrials":131,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1533,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":97},[],{"trials":1530,"activeCount":97},[],{"trials":1532,"activeCount":97},[],{"trials":1534,"activeCount":97},[1535],{"nctId":1508,"briefTitle":1509,"status":120,"phases":1536,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":1537,"interventions":1538},[89],[1515,1516],[1497,1518,1519,1520],{"trials":1540,"activeCount":97},[],{"trials":1542,"activeCount":97},[],{"intervention":1519,"totalTrials":131,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1551,"PHASE4":1557,"NA":1559},{"trials":1546,"activeCount":97},[],{"trials":1548,"activeCount":97},[],{"trials":1550,"activeCount":97},[],{"trials":1552,"activeCount":97},[1553],{"nctId":1508,"briefTitle":1509,"status":120,"phases":1554,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":1555,"interventions":1556},[89],[1515,1516],[1497,1518,1519,1520],{"trials":1558,"activeCount":97},[],{"trials":1560,"activeCount":97},[],{"intervention":1520,"totalTrials":131,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1575,"NA":1577},{"trials":1564,"activeCount":97},[],{"trials":1566,"activeCount":97},[],{"trials":1568,"activeCount":97},[],{"trials":1570,"activeCount":97},[1571],{"nctId":1508,"briefTitle":1509,"status":120,"phases":1572,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":1573,"interventions":1574},[89],[1515,1516],[1497,1518,1519,1520],{"trials":1576,"activeCount":97},[],{"trials":1578,"activeCount":97},[],{"intervention":1580,"totalTrials":131,"cells":1581},"CT-P17 SC",{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1600,"NA":1602},{"trials":1583,"activeCount":97},[],{"trials":1585,"activeCount":97},[],{"trials":1587,"activeCount":97},[],{"trials":1589,"activeCount":97},[1590],{"nctId":1591,"briefTitle":1592,"status":120,"phases":1593,"primaryCompletion":1594,"completion":1442,"start":1595,"enrollment":1596,"conditions":1597,"interventions":1598},"NCT03789292","A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis",[89],"2019-10-08","2018-11-26",648,[17],[1580,1599],"Humira SC",{"trials":1601,"activeCount":97},[],{"trials":1603,"activeCount":97},[],{"intervention":1599,"totalTrials":131,"cells":1605},{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1610,"PHASE3":1612,"PHASE4":1618,"NA":1620},{"trials":1607,"activeCount":97},[],{"trials":1609,"activeCount":97},[],{"trials":1611,"activeCount":97},[],{"trials":1613,"activeCount":97},[1614],{"nctId":1591,"briefTitle":1592,"status":120,"phases":1615,"primaryCompletion":1594,"completion":1442,"start":1595,"enrollment":1596,"conditions":1616,"interventions":1617},[89],[17],[1580,1599],{"trials":1619,"activeCount":97},[],{"trials":1621,"activeCount":97},[],{"intervention":1362,"totalTrials":131,"cells":1623},{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1630,"PHASE4":1636,"NA":1638},{"trials":1625,"activeCount":97},[],{"trials":1627,"activeCount":97},[],{"trials":1629,"activeCount":97},[],{"trials":1631,"activeCount":97},[1632],{"nctId":1352,"briefTitle":1353,"status":120,"phases":1633,"primaryCompletion":1355,"completion":1356,"start":1357,"enrollment":1358,"conditions":1634,"interventions":1635},[89],[1360],[1329,1362],{"trials":1637,"activeCount":97},[],{"trials":1639,"activeCount":97},[],{"intervention":895,"totalTrials":131,"cells":1641},{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1648,"PHASE4":1654,"NA":1656},{"trials":1643,"activeCount":97},[],{"trials":1645,"activeCount":97},[],{"trials":1647,"activeCount":97},[],{"trials":1649,"activeCount":97},[1650],{"nctId":886,"briefTitle":887,"status":120,"phases":1651,"primaryCompletion":889,"completion":890,"start":891,"enrollment":892,"conditions":1652,"interventions":1653},[89],[555],[854,895],{"trials":1655,"activeCount":97},[],{"trials":1657,"activeCount":97},[],{"intervention":968,"totalTrials":131,"cells":1659},{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1672,"NA":1674},{"trials":1661,"activeCount":97},[],{"trials":1663,"activeCount":97},[],{"trials":1665,"activeCount":97},[],{"trials":1667,"activeCount":97},[1668],{"nctId":957,"briefTitle":958,"status":120,"phases":1669,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":1670,"interventions":1671},[89],[965],[946,967,968,969,970],{"trials":1673,"activeCount":97},[],{"trials":1675,"activeCount":97},[],{"intervention":969,"totalTrials":131,"cells":1677},{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1690,"NA":1692},{"trials":1679,"activeCount":97},[],{"trials":1681,"activeCount":97},[],{"trials":1683,"activeCount":97},[],{"trials":1685,"activeCount":97},[1686],{"nctId":957,"briefTitle":958,"status":120,"phases":1687,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":1688,"interventions":1689},[89],[965],[946,967,968,969,970],{"trials":1691,"activeCount":97},[],{"trials":1693,"activeCount":97},[],{"intervention":970,"totalTrials":131,"cells":1695},{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1702,"PHASE4":1708,"NA":1710},{"trials":1697,"activeCount":97},[],{"trials":1699,"activeCount":97},[],{"trials":1701,"activeCount":97},[],{"trials":1703,"activeCount":97},[1704],{"nctId":957,"briefTitle":958,"status":120,"phases":1705,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":1706,"interventions":1707},[89],[965],[946,967,968,969,970],{"trials":1709,"activeCount":97},[],{"trials":1711,"activeCount":97},[],{"intervention":1066,"totalTrials":131,"cells":1713},{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1718,"PHASE3":1720,"PHASE4":1726,"NA":1728},{"trials":1715,"activeCount":97},[],{"trials":1717,"activeCount":97},[],{"trials":1719,"activeCount":97},[],{"trials":1721,"activeCount":97},[1722],{"nctId":1057,"briefTitle":1058,"status":120,"phases":1723,"primaryCompletion":1060,"completion":1061,"start":1062,"enrollment":1063,"conditions":1724,"interventions":1725},[89],[17],[1024,1066],{"trials":1727,"activeCount":97},[],{"trials":1729,"activeCount":97},[],{"intervention":1731,"totalTrials":131,"cells":1732},"AZM X mg + AML Y mg",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1758,"NA":1760},{"trials":1734,"activeCount":97},[],{"trials":1736,"activeCount":97},[],{"trials":1738,"activeCount":97},[],{"trials":1740,"activeCount":97},[1741],{"nctId":1742,"briefTitle":1743,"status":120,"phases":1744,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1750},"NCT05385770","Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects",[89],"2024-07-11","2024-07-19","2022-07-08",890,[25],[1731,1751,1752,1753,1754,1755,1756,1757],"AZM X mg + AML Y' mg","AZM X' mg + AML Y mg","AZM X' mg + AML Y' mg","AZM X mg","AZM X' mg","AML Y mg","AML Y' mg",{"trials":1759,"activeCount":97},[],{"trials":1761,"activeCount":97},[],{"intervention":1751,"totalTrials":131,"cells":1763},{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1770,"PHASE4":1776,"NA":1778},{"trials":1765,"activeCount":97},[],{"trials":1767,"activeCount":97},[],{"trials":1769,"activeCount":97},[],{"trials":1771,"activeCount":97},[1772],{"nctId":1742,"briefTitle":1743,"status":120,"phases":1773,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1774,"interventions":1775},[89],[25],[1731,1751,1752,1753,1754,1755,1756,1757],{"trials":1777,"activeCount":97},[],{"trials":1779,"activeCount":97},[],{"intervention":1752,"totalTrials":131,"cells":1781},{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1788,"PHASE4":1794,"NA":1796},{"trials":1783,"activeCount":97},[],{"trials":1785,"activeCount":97},[],{"trials":1787,"activeCount":97},[],{"trials":1789,"activeCount":97},[1790],{"nctId":1742,"briefTitle":1743,"status":120,"phases":1791,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1792,"interventions":1793},[89],[25],[1731,1751,1752,1753,1754,1755,1756,1757],{"trials":1795,"activeCount":97},[],{"trials":1797,"activeCount":97},[],{"intervention":1753,"totalTrials":131,"cells":1799},{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1806,"PHASE4":1812,"NA":1814},{"trials":1801,"activeCount":97},[],{"trials":1803,"activeCount":97},[],{"trials":1805,"activeCount":97},[],{"trials":1807,"activeCount":97},[1808],{"nctId":1742,"briefTitle":1743,"status":120,"phases":1809,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1810,"interventions":1811},[89],[25],[1731,1751,1752,1753,1754,1755,1756,1757],{"trials":1813,"activeCount":97},[],{"trials":1815,"activeCount":97},[],{"intervention":1754,"totalTrials":131,"cells":1817},{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1824,"PHASE4":1830,"NA":1832},{"trials":1819,"activeCount":97},[],{"trials":1821,"activeCount":97},[],{"trials":1823,"activeCount":97},[],{"trials":1825,"activeCount":97},[1826],{"nctId":1742,"briefTitle":1743,"status":120,"phases":1827,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1828,"interventions":1829},[89],[25],[1731,1751,1752,1753,1754,1755,1756,1757],{"trials":1831,"activeCount":97},[],{"trials":1833,"activeCount":97},[],{"intervention":1755,"totalTrials":131,"cells":1835},{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1842,"PHASE4":1848,"NA":1850},{"trials":1837,"activeCount":97},[],{"trials":1839,"activeCount":97},[],{"trials":1841,"activeCount":97},[],{"trials":1843,"activeCount":97},[1844],{"nctId":1742,"briefTitle":1743,"status":120,"phases":1845,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1846,"interventions":1847},[89],[25],[1731,1751,1752,1753,1754,1755,1756,1757],{"trials":1849,"activeCount":97},[],{"trials":1851,"activeCount":97},[],{"intervention":1756,"totalTrials":131,"cells":1853},{"EARLY_PHASE1":1854,"PHASE1":1856,"PHASE2":1858,"PHASE3":1860,"PHASE4":1866,"NA":1868},{"trials":1855,"activeCount":97},[],{"trials":1857,"activeCount":97},[],{"trials":1859,"activeCount":97},[],{"trials":1861,"activeCount":97},[1862],{"nctId":1742,"briefTitle":1743,"status":120,"phases":1863,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1864,"interventions":1865},[89],[25],[1731,1751,1752,1753,1754,1755,1756,1757],{"trials":1867,"activeCount":97},[],{"trials":1869,"activeCount":97},[],{"intervention":1757,"totalTrials":131,"cells":1871},{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1878,"PHASE4":1884,"NA":1886},{"trials":1873,"activeCount":97},[],{"trials":1875,"activeCount":97},[],{"trials":1877,"activeCount":97},[],{"trials":1879,"activeCount":97},[1880],{"nctId":1742,"briefTitle":1743,"status":120,"phases":1881,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1882,"interventions":1883},[89],[25],[1731,1751,1752,1753,1754,1755,1756,1757],{"trials":1885,"activeCount":97},[],{"trials":1887,"activeCount":97},[],{"intervention":1889,"totalTrials":131,"cells":1890},"CT-P63 and CT-P66 \u002F Placebo",{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1897,"PHASE4":1910,"NA":1912},{"trials":1892,"activeCount":97},[],{"trials":1894,"activeCount":97},[],{"trials":1896,"activeCount":97},[],{"trials":1898,"activeCount":97},[1899],{"nctId":1900,"briefTitle":1901,"status":1902,"phases":1903,"primaryCompletion":1904,"completion":1905,"start":1906,"enrollment":97,"conditions":1907,"interventions":1909},"NCT05224856","To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen","WITHDRAWN",[89],"2022-11","2023-01","2022-04",[1908],"COVID-19",[1889],{"trials":1911,"activeCount":97},[],{"trials":1913,"activeCount":97},[],{"intervention":128,"totalTrials":131,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1922,"PHASE4":1928,"NA":1930},{"trials":1917,"activeCount":97},[],{"trials":1919,"activeCount":97},[],{"trials":1921,"activeCount":97},[],{"trials":1923,"activeCount":97},[1924],{"nctId":118,"briefTitle":119,"status":120,"phases":1925,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":1926,"interventions":1927},[89],[111],[128,129,130,60],{"trials":1929,"activeCount":97},[],{"trials":1931,"activeCount":97},[],{"intervention":129,"totalTrials":131,"cells":1933},{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1946,"NA":1948},{"trials":1935,"activeCount":97},[],{"trials":1937,"activeCount":97},[],{"trials":1939,"activeCount":97},[],{"trials":1941,"activeCount":97},[1942],{"nctId":118,"briefTitle":119,"status":120,"phases":1943,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":1944,"interventions":1945},[89],[111],[128,129,130,60],{"trials":1947,"activeCount":97},[],{"trials":1949,"activeCount":97},[],{"intervention":1951,"totalTrials":131,"cells":1952},"CT-P47 AI",{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1959,"PHASE4":1971,"NA":1973},{"trials":1954,"activeCount":97},[],{"trials":1956,"activeCount":97},[],{"trials":1958,"activeCount":97},[],{"trials":1960,"activeCount":97},[1961],{"nctId":1962,"briefTitle":1963,"status":1033,"phases":1964,"primaryCompletion":1965,"completion":1966,"start":1967,"enrollment":772,"conditions":1968,"interventions":1969},"NCT05725434","A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis",[89],"2023-04-01","2023-07-31","2023-02-06",[17],[1951,1970],"CT-P47 PFS",{"trials":1972,"activeCount":97},[],{"trials":1974,"activeCount":97},[],{"intervention":1970,"totalTrials":131,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1983,"PHASE4":1989,"NA":1991},{"trials":1978,"activeCount":97},[],{"trials":1980,"activeCount":97},[],{"trials":1982,"activeCount":97},[],{"trials":1984,"activeCount":97},[1985],{"nctId":1962,"briefTitle":1963,"status":1033,"phases":1986,"primaryCompletion":1965,"completion":1966,"start":1967,"enrollment":772,"conditions":1987,"interventions":1988},[89],[17],[1951,1970],{"trials":1990,"activeCount":97},[],{"trials":1992,"activeCount":97},[],{"intervention":981,"totalTrials":131,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2001,"PHASE4":2007,"NA":2009},{"trials":1996,"activeCount":97},[],{"trials":1998,"activeCount":97},[],{"trials":2000,"activeCount":97},[],{"trials":2002,"activeCount":97},[2003],{"nctId":972,"briefTitle":973,"status":120,"phases":2004,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":2005,"interventions":2006},[89],[17],[967,946,981],{"trials":2008,"activeCount":97},[],{"trials":2010,"activeCount":97},[],{"intervention":2012,"totalTrials":131,"cells":2013},"CT-P27",{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2031,"PHASE4":2033,"NA":2035},{"trials":2015,"activeCount":97},[],{"trials":2017,"activeCount":97},[],{"trials":2019,"activeCount":97},[2020],{"nctId":2021,"briefTitle":2022,"status":120,"phases":2023,"primaryCompletion":2024,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2030},"NCT02071914","A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model",[88],"2014-05-19","2014-06-19","2014-02-15",81,[2029],"Influenza A",[2012],{"trials":2032,"activeCount":97},[],{"trials":2034,"activeCount":97},[],{"trials":2036,"activeCount":97},[],{"intervention":2038,"totalTrials":131,"cells":2039},"CT-P27 90 mg\u002Fkg",{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2041,"activeCount":97},[],{"trials":2043,"activeCount":97},[],{"trials":2045,"activeCount":97},[2046],{"nctId":2047,"briefTitle":2048,"status":2049,"phases":2050,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":2055,"interventions":2056},"NCT03511066","A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection","TERMINATED",[88],"2018-03-09","2018-06-15","2016-12-09",228,[2029],[2038,2057],"CT-P27 45 mg\u002Fkg",{"trials":2059,"activeCount":97},[],{"trials":2061,"activeCount":97},[],{"trials":2063,"activeCount":97},[],{"intervention":2057,"totalTrials":131,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2067,"activeCount":97},[],{"trials":2069,"activeCount":97},[],{"trials":2071,"activeCount":97},[2072],{"nctId":2047,"briefTitle":2048,"status":2049,"phases":2073,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":2074,"interventions":2075},[88],[2029],[2038,2057],{"trials":2077,"activeCount":97},[],{"trials":2079,"activeCount":97},[],{"trials":2081,"activeCount":97},[],{"intervention":2083,"totalTrials":34,"cells":2084},"L04RD1",{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2119,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2086,"activeCount":97},[],{"trials":2088,"activeCount":97},[2089,2100,2110],{"nctId":2090,"briefTitle":2091,"status":120,"phases":2092,"primaryCompletion":2093,"completion":2094,"start":2095,"enrollment":2096,"conditions":2097,"interventions":2098},"NCT05568121","A Bioequivalence Study of L04TD1 Compared to Administration of L04RD1 in Healthy Volunteers",[87],"2022-10-09","2022-10-27","2022-09-01",50,[20],[2083,2099,2099,2083],"L04TD1",{"nctId":2101,"briefTitle":2102,"status":120,"phases":2103,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":2096,"conditions":2107,"interventions":2108},"NCT05581693","A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy Volunteers",[87],"2022-11-01","2022-11-29","2022-09-30",[20],[2083,2109,2109,2083],"L04TD2",{"nctId":2111,"briefTitle":2112,"status":120,"phases":2113,"primaryCompletion":2114,"completion":1060,"start":2115,"enrollment":2096,"conditions":2116,"interventions":2117},"NCT05993806","A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers",[87],"2023-06-12","2023-06-02",[25],[2083,2118],"L04TD3",{"trials":2120,"activeCount":97},[],{"trials":2122,"activeCount":97},[],{"trials":2124,"activeCount":97},[],{"trials":2126,"activeCount":97},[],{"intervention":2128,"totalTrials":150,"cells":2129},"rituximab",{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2151,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2131,"activeCount":97},[],{"trials":2133,"activeCount":97},[2134,2143],{"nctId":2135,"briefTitle":2136,"status":120,"phases":2137,"primaryCompletion":2138,"completion":2139,"start":2140,"enrollment":782,"conditions":2141,"interventions":2142},"NCT01534884","Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis",[87],"2013-08","2014-02","2012-02",[17],[2128],{"nctId":2144,"briefTitle":2145,"status":2049,"phases":2146,"primaryCompletion":2147,"completion":2147,"start":2140,"enrollment":131,"conditions":2148,"interventions":2150},"NCT01534949","Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial",[87],"2013-02",[2149],"Diffuse Large B-Cell Lymphoma",[2128],{"trials":2152,"activeCount":97},[],{"trials":2154,"activeCount":97},[],{"trials":2156,"activeCount":97},[],{"trials":2158,"activeCount":97},[],{"intervention":2160,"totalTrials":150,"cells":2161},"CT-G20",{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2188,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2163,"activeCount":97},[],{"trials":2165,"activeCount":97},[2166,2176],{"nctId":2167,"briefTitle":2168,"status":2049,"phases":2169,"primaryCompletion":2170,"completion":2170,"start":2171,"enrollment":2172,"conditions":2173,"interventions":2175},"NCT04418297","A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy",[87],"2022-11-22","2020-10-23",23,[2174],"Cardiomyopathy, Hypertrophic Obstructive",[2160],{"nctId":2177,"briefTitle":2178,"status":120,"phases":2179,"primaryCompletion":2180,"completion":2180,"start":2181,"enrollment":2182,"conditions":2183,"interventions":2184},"NCT03918967","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants",[87],"2020-06-06","2019-04-08",72,[20],[2185,2160,2186,2187],"CT-G11","CT-G11 Placebo","CT-G20 Placebo",{"trials":2189,"activeCount":97},[],{"trials":2191,"activeCount":97},[],{"trials":2193,"activeCount":97},[],{"trials":2195,"activeCount":97},[],{"intervention":2197,"totalTrials":131,"cells":2198},"CT-L01",{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2214,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2200,"activeCount":97},[],{"trials":2202,"activeCount":97},[2203],{"nctId":2204,"briefTitle":2205,"status":120,"phases":2206,"primaryCompletion":2207,"completion":2208,"start":2209,"enrollment":402,"conditions":2210,"interventions":2211},"NCT05363384","A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers",[87],"2022-06-21","2022-07-12","2022-06-11",[20],[2197,2212,2213],"Alogliptin Benzoate 25 mg","Metformin HCl XR 1,000 mg",{"trials":2215,"activeCount":97},[],{"trials":2217,"activeCount":97},[],{"trials":2219,"activeCount":97},[],{"trials":2221,"activeCount":97},[],{"intervention":2212,"totalTrials":131,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2232,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":97},[],{"trials":2227,"activeCount":97},[2228],{"nctId":2204,"briefTitle":2205,"status":120,"phases":2229,"primaryCompletion":2207,"completion":2208,"start":2209,"enrollment":402,"conditions":2230,"interventions":2231},[87],[20],[2197,2212,2213],{"trials":2233,"activeCount":97},[],{"trials":2235,"activeCount":97},[],{"trials":2237,"activeCount":97},[],{"trials":2239,"activeCount":97},[],{"intervention":2213,"totalTrials":131,"cells":2241},{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2256},{"trials":2243,"activeCount":97},[],{"trials":2245,"activeCount":97},[2246],{"nctId":2204,"briefTitle":2205,"status":120,"phases":2247,"primaryCompletion":2207,"completion":2208,"start":2209,"enrollment":402,"conditions":2248,"interventions":2249},[87],[20],[2197,2212,2213],{"trials":2251,"activeCount":97},[],{"trials":2253,"activeCount":97},[],{"trials":2255,"activeCount":97},[],{"trials":2257,"activeCount":97},[],{"intervention":2259,"totalTrials":131,"cells":2260},"CT-L01 12.5\u002F500 mg",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2276,"PHASE3":2278,"PHASE4":2280,"NA":2282},{"trials":2262,"activeCount":97},[],{"trials":2264,"activeCount":97},[2265],{"nctId":2266,"briefTitle":2267,"status":120,"phases":2268,"primaryCompletion":2269,"completion":2270,"start":2271,"enrollment":402,"conditions":2272,"interventions":2273},"NCT05363592","A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers",[87],"2022-07-05","2022-07-25","2022-06-25",[20],[2259,2274,2275],"Alogliptin Benzoate 12.5 mg","Metformin HCl XR 500 mg",{"trials":2277,"activeCount":97},[],{"trials":2279,"activeCount":97},[],{"trials":2281,"activeCount":97},[],{"trials":2283,"activeCount":97},[],{"intervention":2274,"totalTrials":131,"cells":2285},{"EARLY_PHASE1":2286,"PHASE1":2288,"PHASE2":2294,"PHASE3":2296,"PHASE4":2298,"NA":2300},{"trials":2287,"activeCount":97},[],{"trials":2289,"activeCount":97},[2290],{"nctId":2266,"briefTitle":2267,"status":120,"phases":2291,"primaryCompletion":2269,"completion":2270,"start":2271,"enrollment":402,"conditions":2292,"interventions":2293},[87],[20],[2259,2274,2275],{"trials":2295,"activeCount":97},[],{"trials":2297,"activeCount":97},[],{"trials":2299,"activeCount":97},[],{"trials":2301,"activeCount":97},[],{"intervention":2275,"totalTrials":131,"cells":2303},{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2312,"PHASE3":2314,"PHASE4":2316,"NA":2318},{"trials":2305,"activeCount":97},[],{"trials":2307,"activeCount":97},[2308],{"nctId":2266,"briefTitle":2267,"status":120,"phases":2309,"primaryCompletion":2269,"completion":2270,"start":2271,"enrollment":402,"conditions":2310,"interventions":2311},[87],[20],[2259,2274,2275],{"trials":2313,"activeCount":97},[],{"trials":2315,"activeCount":97},[],{"trials":2317,"activeCount":97},[],{"trials":2319,"activeCount":97},[],{"intervention":2321,"totalTrials":131,"cells":2322},"CTL02",{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2338,"PHASE3":2340,"PHASE4":2342,"NA":2344},{"trials":2324,"activeCount":97},[],{"trials":2326,"activeCount":97},[2327],{"nctId":2328,"briefTitle":2329,"status":120,"phases":2330,"primaryCompletion":2331,"completion":2332,"start":496,"enrollment":2333,"conditions":2334,"interventions":2335},"NCT07128654","A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers",[87],"2025-10-05","2025-10-26",40,[20],[2321,2336,2337],"CTL0201","CTL0202",{"trials":2339,"activeCount":97},[],{"trials":2341,"activeCount":97},[],{"trials":2343,"activeCount":97},[],{"trials":2345,"activeCount":97},[],{"intervention":2336,"totalTrials":131,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2356,"PHASE3":2358,"PHASE4":2360,"NA":2362},{"trials":2349,"activeCount":97},[],{"trials":2351,"activeCount":97},[2352],{"nctId":2328,"briefTitle":2329,"status":120,"phases":2353,"primaryCompletion":2331,"completion":2332,"start":496,"enrollment":2333,"conditions":2354,"interventions":2355},[87],[20],[2321,2336,2337],{"trials":2357,"activeCount":97},[],{"trials":2359,"activeCount":97},[],{"trials":2361,"activeCount":97},[],{"trials":2363,"activeCount":97},[],{"intervention":2337,"totalTrials":131,"cells":2365},{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2374,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2367,"activeCount":97},[],{"trials":2369,"activeCount":97},[2370],{"nctId":2328,"briefTitle":2329,"status":120,"phases":2371,"primaryCompletion":2331,"completion":2332,"start":496,"enrollment":2333,"conditions":2372,"interventions":2373},[87],[20],[2321,2336,2337],{"trials":2375,"activeCount":97},[],{"trials":2377,"activeCount":97},[],{"trials":2379,"activeCount":97},[],{"trials":2381,"activeCount":97},[],{"intervention":832,"totalTrials":131,"cells":2383},{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2392,"PHASE3":2394,"PHASE4":2396,"NA":2398},{"trials":2385,"activeCount":97},[],{"trials":2387,"activeCount":97},[2388],{"nctId":823,"briefTitle":824,"status":120,"phases":2389,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":2390,"interventions":2391},[87],[20],[807,832,833],{"trials":2393,"activeCount":97},[],{"trials":2395,"activeCount":97},[],{"trials":2397,"activeCount":97},[],{"trials":2399,"activeCount":97},[],{"intervention":869,"totalTrials":131,"cells":2401},{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2410,"PHASE3":2412,"PHASE4":2414,"NA":2416},{"trials":2403,"activeCount":97},[],{"trials":2405,"activeCount":97},[2406],{"nctId":861,"briefTitle":862,"status":120,"phases":2407,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":2408,"interventions":2409},[87],[33],[854,869,870],{"trials":2411,"activeCount":97},[],{"trials":2413,"activeCount":97},[],{"trials":2415,"activeCount":97},[],{"trials":2417,"activeCount":97},[],{"intervention":870,"totalTrials":131,"cells":2419},{"EARLY_PHASE1":2420,"PHASE1":2422,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2434},{"trials":2421,"activeCount":97},[],{"trials":2423,"activeCount":97},[2424],{"nctId":861,"briefTitle":862,"status":120,"phases":2425,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":2426,"interventions":2427},[87],[33],[854,869,870],{"trials":2429,"activeCount":97},[],{"trials":2431,"activeCount":97},[],{"trials":2433,"activeCount":97},[],{"trials":2435,"activeCount":97},[],{"intervention":188,"totalTrials":131,"cells":2437},{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2446,"PHASE3":2448,"PHASE4":2450,"NA":2452},{"trials":2439,"activeCount":97},[],{"trials":2441,"activeCount":97},[2442],{"nctId":179,"briefTitle":180,"status":120,"phases":2443,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":2444,"interventions":2445},[87],[27],[40,188,189],{"trials":2447,"activeCount":97},[],{"trials":2449,"activeCount":97},[],{"trials":2451,"activeCount":97},[],{"trials":2453,"activeCount":97},[],{"intervention":2455,"totalTrials":131,"cells":2456},"Rituximab, MTX, folic acid",{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2469,"PHASE3":2471,"PHASE4":2473,"NA":2475},{"trials":2458,"activeCount":97},[],{"trials":2460,"activeCount":97},[2461],{"nctId":2462,"briefTitle":2463,"status":120,"phases":2464,"primaryCompletion":2465,"completion":2465,"start":673,"enrollment":2466,"conditions":2467,"interventions":2468},"NCT01873443","Long-Term Efficacy and Safety of CT-P10 in Patients With RA",[87],"2014-10",87,[17],[2455],{"trials":2470,"activeCount":97},[],{"trials":2472,"activeCount":97},[],{"trials":2474,"activeCount":97},[],{"trials":2476,"activeCount":97},[],{"intervention":1345,"totalTrials":131,"cells":2478},{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2487,"PHASE3":2489,"PHASE4":2491,"NA":2493},{"trials":2480,"activeCount":97},[],{"trials":2482,"activeCount":97},[2483],{"nctId":1336,"briefTitle":1337,"status":120,"phases":2484,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":2485,"interventions":2486},[87],[20],[1329,1345,1346],{"trials":2488,"activeCount":97},[],{"trials":2490,"activeCount":97},[],{"trials":2492,"activeCount":97},[],{"trials":2494,"activeCount":97},[],{"intervention":1346,"totalTrials":131,"cells":2496},{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2505,"PHASE3":2507,"PHASE4":2509,"NA":2511},{"trials":2498,"activeCount":97},[],{"trials":2500,"activeCount":97},[2501],{"nctId":1336,"briefTitle":1337,"status":120,"phases":2502,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":2503,"interventions":2504},[87],[20],[1329,1345,1346],{"trials":2506,"activeCount":97},[],{"trials":2508,"activeCount":97},[],{"trials":2510,"activeCount":97},[],{"trials":2512,"activeCount":97},[],{"intervention":2099,"totalTrials":131,"cells":2514},{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2523,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2516,"activeCount":97},[],{"trials":2518,"activeCount":97},[2519],{"nctId":2090,"briefTitle":2091,"status":120,"phases":2520,"primaryCompletion":2093,"completion":2094,"start":2095,"enrollment":2096,"conditions":2521,"interventions":2522},[87],[20],[2083,2099,2099,2083],{"trials":2524,"activeCount":97},[],{"trials":2526,"activeCount":97},[],{"trials":2528,"activeCount":97},[],{"trials":2530,"activeCount":97},[],{"intervention":2109,"totalTrials":131,"cells":2532},{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2541,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2534,"activeCount":97},[],{"trials":2536,"activeCount":97},[2537],{"nctId":2101,"briefTitle":2102,"status":120,"phases":2538,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":2096,"conditions":2539,"interventions":2540},[87],[20],[2083,2109,2109,2083],{"trials":2542,"activeCount":97},[],{"trials":2544,"activeCount":97},[],{"trials":2546,"activeCount":97},[],{"trials":2548,"activeCount":97},[],{"intervention":2550,"totalTrials":131,"cells":2551},"CT-L01 12.5\u002F1,000 mg",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2553,"activeCount":97},[],{"trials":2555,"activeCount":97},[2556],{"nctId":2557,"briefTitle":2558,"status":120,"phases":2559,"primaryCompletion":2560,"completion":2270,"start":2561,"enrollment":2562,"conditions":2563,"interventions":2564},"NCT05364164","A Food Effect Study of CT-L01 After Oral Administration in Healthy Volunteers",[87],"2022-07-19","2022-07-09",24,[20],[2550,2550],{"trials":2566,"activeCount":97},[],{"trials":2568,"activeCount":97},[],{"trials":2570,"activeCount":97},[],{"trials":2572,"activeCount":97},[],{"intervention":1041,"totalTrials":131,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2589},{"trials":2576,"activeCount":97},[],{"trials":2578,"activeCount":97},[2579],{"nctId":1031,"briefTitle":1032,"status":1033,"phases":2580,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":2581,"interventions":2582},[87],[33],[1024,1041],{"trials":2584,"activeCount":97},[],{"trials":2586,"activeCount":97},[],{"trials":2588,"activeCount":97},[],{"trials":2590,"activeCount":97},[],{"intervention":2592,"totalTrials":131,"cells":2593},"Drug: Treatment A",{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2610,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2595,"activeCount":97},[],{"trials":2597,"activeCount":97},[2598],{"nctId":2599,"briefTitle":2600,"status":120,"phases":2601,"primaryCompletion":2602,"completion":2603,"start":2604,"enrollment":2605,"conditions":2606,"interventions":2607},"NCT05009368","A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers",[87],"2021-10-08","2021-10-15","2021-07-23",41,[1381],[2592,2608,2609],"Drug: Treatment B","Drug: Treatment C",{"trials":2611,"activeCount":97},[],{"trials":2613,"activeCount":97},[],{"trials":2615,"activeCount":97},[],{"trials":2617,"activeCount":97},[],{"intervention":2608,"totalTrials":131,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2628,"PHASE3":2630,"PHASE4":2632,"NA":2634},{"trials":2621,"activeCount":97},[],{"trials":2623,"activeCount":97},[2624],{"nctId":2599,"briefTitle":2600,"status":120,"phases":2625,"primaryCompletion":2602,"completion":2603,"start":2604,"enrollment":2605,"conditions":2626,"interventions":2627},[87],[1381],[2592,2608,2609],{"trials":2629,"activeCount":97},[],{"trials":2631,"activeCount":97},[],{"trials":2633,"activeCount":97},[],{"trials":2635,"activeCount":97},[],{"intervention":2609,"totalTrials":131,"cells":2637},{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2646,"PHASE3":2648,"PHASE4":2650,"NA":2652},{"trials":2639,"activeCount":97},[],{"trials":2641,"activeCount":97},[2642],{"nctId":2599,"briefTitle":2600,"status":120,"phases":2643,"primaryCompletion":2602,"completion":2603,"start":2604,"enrollment":2605,"conditions":2644,"interventions":2645},[87],[1381],[2592,2608,2609],{"trials":2647,"activeCount":97},[],{"trials":2649,"activeCount":97},[],{"trials":2651,"activeCount":97},[],{"trials":2653,"activeCount":97},[],{"intervention":2655,"totalTrials":131,"cells":2656},"CT-P63",{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2670,"PHASE3":2672,"PHASE4":2674,"NA":2676},{"trials":2658,"activeCount":97},[],{"trials":2660,"activeCount":97},[2661],{"nctId":2662,"briefTitle":2663,"status":120,"phases":2664,"primaryCompletion":2665,"completion":2666,"start":2667,"enrollment":2562,"conditions":2668,"interventions":2669},"NCT05017168","To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects",[87],"2021-11-12","2022-01-25","2021-10-11",[29],[2655],{"trials":2671,"activeCount":97},[],{"trials":2673,"activeCount":97},[],{"trials":2675,"activeCount":97},[],{"trials":2677,"activeCount":97},[],{"intervention":775,"totalTrials":131,"cells":2679},{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2688,"PHASE3":2690,"PHASE4":2692,"NA":2694},{"trials":2681,"activeCount":97},[],{"trials":2683,"activeCount":97},[2684],{"nctId":767,"briefTitle":768,"status":120,"phases":2685,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":2686,"interventions":2687},[87],[27],[760,775],{"trials":2689,"activeCount":97},[],{"trials":2691,"activeCount":97},[],{"trials":2693,"activeCount":97},[],{"trials":2695,"activeCount":97},[],{"intervention":1384,"totalTrials":131,"cells":2697},{"EARLY_PHASE1":2698,"PHASE1":2700,"PHASE2":2706,"PHASE3":2708,"PHASE4":2710,"NA":2712},{"trials":2699,"activeCount":97},[],{"trials":2701,"activeCount":97},[2702],{"nctId":1375,"briefTitle":1376,"status":120,"phases":2703,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":477,"conditions":2704,"interventions":2705},[87],[1381],[1383,1384],{"trials":2707,"activeCount":97},[],{"trials":2709,"activeCount":97},[],{"trials":2711,"activeCount":97},[],{"trials":2713,"activeCount":97},[],{"intervention":2715,"totalTrials":131,"cells":2716},"CT-P6 SC",{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2731,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2718,"activeCount":97},[],{"trials":2720,"activeCount":97},[2721],{"nctId":2722,"briefTitle":2723,"status":120,"phases":2724,"primaryCompletion":2725,"completion":2725,"start":2726,"enrollment":2727,"conditions":2728,"interventions":2729},"NCT06687928","To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)",[87],"2025-08-05","2025-03-26",200,[20],[2715,2730],"EU-Approved Herceptin SC",{"trials":2732,"activeCount":97},[],{"trials":2734,"activeCount":97},[],{"trials":2736,"activeCount":97},[],{"trials":2738,"activeCount":97},[],{"intervention":2730,"totalTrials":131,"cells":2740},{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2749,"PHASE3":2751,"PHASE4":2753,"NA":2755},{"trials":2742,"activeCount":97},[],{"trials":2744,"activeCount":97},[2745],{"nctId":2722,"briefTitle":2723,"status":120,"phases":2746,"primaryCompletion":2725,"completion":2725,"start":2726,"enrollment":2727,"conditions":2747,"interventions":2748},[87],[20],[2715,2730],{"trials":2750,"activeCount":97},[],{"trials":2752,"activeCount":97},[],{"trials":2754,"activeCount":97},[],{"trials":2756,"activeCount":97},[],{"intervention":1206,"totalTrials":131,"cells":2758},{"EARLY_PHASE1":2759,"PHASE1":2761,"PHASE2":2767,"PHASE3":2769,"PHASE4":2771,"NA":2773},{"trials":2760,"activeCount":97},[],{"trials":2762,"activeCount":97},[2763],{"nctId":1196,"briefTitle":1197,"status":120,"phases":2764,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":2765,"interventions":2766},[87],[20],[1189,1205,1189,1205,1206],{"trials":2768,"activeCount":97},[],{"trials":2770,"activeCount":97},[],{"trials":2772,"activeCount":97},[],{"trials":2774,"activeCount":97},[],{"intervention":2776,"totalTrials":131,"cells":2777},"CTL0801",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2792,"PHASE3":2794,"PHASE4":2796,"NA":2798},{"trials":2779,"activeCount":97},[],{"trials":2781,"activeCount":97},[2782],{"nctId":2783,"briefTitle":2784,"status":120,"phases":2785,"primaryCompletion":2786,"completion":2787,"start":2604,"enrollment":2788,"conditions":2789,"interventions":2790},"NCT05002244","A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers",[87],"2021-08-29","2021-09-13",37,[1381],[2776,2791,2776],"CTL0802",{"trials":2793,"activeCount":97},[],{"trials":2795,"activeCount":97},[],{"trials":2797,"activeCount":97},[],{"trials":2799,"activeCount":97},[],{"intervention":2791,"totalTrials":131,"cells":2801},{"EARLY_PHASE1":2802,"PHASE1":2804,"PHASE2":2810,"PHASE3":2812,"PHASE4":2814,"NA":2816},{"trials":2803,"activeCount":97},[],{"trials":2805,"activeCount":97},[2806],{"nctId":2783,"briefTitle":2784,"status":120,"phases":2807,"primaryCompletion":2786,"completion":2787,"start":2604,"enrollment":2788,"conditions":2808,"interventions":2809},[87],[1381],[2776,2791,2776],{"trials":2811,"activeCount":97},[],{"trials":2813,"activeCount":97},[],{"trials":2815,"activeCount":97},[],{"trials":2817,"activeCount":97},[],{"intervention":418,"totalTrials":131,"cells":2819},{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2828,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2821,"activeCount":97},[],{"trials":2823,"activeCount":97},[2824],{"nctId":409,"briefTitle":410,"status":120,"phases":2825,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":2826,"interventions":2827},[87],[404],[50,406,418],{"trials":2829,"activeCount":97},[],{"trials":2831,"activeCount":97},[],{"trials":2833,"activeCount":97},[],{"trials":2835,"activeCount":97},[],{"intervention":2185,"totalTrials":131,"cells":2837},{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2839,"activeCount":97},[],{"trials":2841,"activeCount":97},[2842],{"nctId":2177,"briefTitle":2178,"status":120,"phases":2843,"primaryCompletion":2180,"completion":2180,"start":2181,"enrollment":2182,"conditions":2844,"interventions":2845},[87],[20],[2185,2160,2186,2187],{"trials":2847,"activeCount":97},[],{"trials":2849,"activeCount":97},[],{"trials":2851,"activeCount":97},[],{"trials":2853,"activeCount":97},[],{"intervention":2186,"totalTrials":131,"cells":2855},{"EARLY_PHASE1":2856,"PHASE1":2858,"PHASE2":2864,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2857,"activeCount":97},[],{"trials":2859,"activeCount":97},[2860],{"nctId":2177,"briefTitle":2178,"status":120,"phases":2861,"primaryCompletion":2180,"completion":2180,"start":2181,"enrollment":2182,"conditions":2862,"interventions":2863},[87],[20],[2185,2160,2186,2187],{"trials":2865,"activeCount":97},[],{"trials":2867,"activeCount":97},[],{"trials":2869,"activeCount":97},[],{"trials":2871,"activeCount":97},[],{"intervention":2187,"totalTrials":131,"cells":2873},{"EARLY_PHASE1":2874,"PHASE1":2876,"PHASE2":2882,"PHASE3":2884,"PHASE4":2886,"NA":2888},{"trials":2875,"activeCount":97},[],{"trials":2877,"activeCount":97},[2878],{"nctId":2177,"briefTitle":2178,"status":120,"phases":2879,"primaryCompletion":2180,"completion":2180,"start":2181,"enrollment":2182,"conditions":2880,"interventions":2881},[87],[20],[2185,2160,2186,2187],{"trials":2883,"activeCount":97},[],{"trials":2885,"activeCount":97},[],{"trials":2887,"activeCount":97},[],{"trials":2889,"activeCount":97},[],{"intervention":2118,"totalTrials":131,"cells":2891},{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2900,"PHASE3":2902,"PHASE4":2904,"NA":2906},{"trials":2893,"activeCount":97},[],{"trials":2895,"activeCount":97},[2896],{"nctId":2111,"briefTitle":2112,"status":120,"phases":2897,"primaryCompletion":2114,"completion":1060,"start":2115,"enrollment":2096,"conditions":2898,"interventions":2899},[87],[25],[2083,2118],{"trials":2901,"activeCount":97},[],{"trials":2903,"activeCount":97},[],{"trials":2905,"activeCount":97},[],{"trials":2907,"activeCount":97},[],{"intervention":2909,"totalTrials":131,"cells":2910},"Azilsartan Medoxomil",{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2917,"PHASE4":2919,"NA":2921},{"trials":2912,"activeCount":97},[],{"trials":2914,"activeCount":97},[],{"trials":2916,"activeCount":97},[],{"trials":2918,"activeCount":97},[],{"trials":2920,"activeCount":97},[],{"trials":2922,"activeCount":97},[2923],{"nctId":2924,"briefTitle":2925,"status":120,"phases":2926,"primaryCompletion":2927,"completion":2927,"start":2928,"enrollment":2929,"conditions":2930,"interventions":2931},"NCT04470817","A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea",[],"2023-05-25","2018-08-07",3438,[25],[2909],{"intervention":2933,"totalTrials":131,"cells":2934},"Adalimumab",{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2939,"PHASE3":2941,"PHASE4":2943,"NA":2945},{"trials":2936,"activeCount":97},[],{"trials":2938,"activeCount":97},[],{"trials":2940,"activeCount":97},[],{"trials":2942,"activeCount":97},[],{"trials":2944,"activeCount":97},[],{"trials":2946,"activeCount":97},[2947],{"nctId":2948,"briefTitle":2949,"status":1033,"phases":2950,"primaryCompletion":2951,"completion":2952,"start":2953,"enrollment":1038,"conditions":2954,"interventions":2957},"NCT05427942","Yuflyma® (Adalimumab), Patient Experience After Switching",[],"2022-12-31","2023-03-01","2022-06-03",[17,2955,2956,554,595,1182],"Ankylosing Spondylarthritis","Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis",[2933]]